Sufotidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sufotidine
Sufotidine.svg
Clinical data
Routes of
administration		 Oral
ATC code None
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number 80343-63-1
PubChem (CID) 71763
ChemSpider 64802
UNII 56B0591Y76
KEGG D05939
Chemical and physical data
Formula C20H31N5O3S
Molar mass 421.556 g/mol
3D model (Jmol) Interactive image

Sufotidine (INN,[1] USAN, codenamed AH25352) is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant by Glaxo (now GlaxoSmithKline).[2] It was planned to be a follow-up compound to ranitidine (Zantac).[3] When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity[4] thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole.[5] Its development was terminated in 1989[6] from phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents.[7]

Synthesis[edit]

Sufotidine synthesis.png

See also[edit]

  • Lavoltidine (previously known as loxtidine) — a similar compound in which methylsulfone group is replaced with hydroxyl

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1986, Vol. 40, No. 6. Recommended International Nonproprietary Names (Rec. INN): List 26" (PDF). World Health Organization. p. 9. Retrieved 12 January 2016. 
  2. ^ "Drug Profile: Sufotidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016. 
  3. ^ "Glaxo Plans to Follow Up Zantac with Long-acting Sufotidine; H2 Antagonist Is One of Seven Drugs Targeted for Worldwide Marketing Applications in 1988–90". Pharma & MedTech Business Intelligence. Informa Business Intelligence, Inc., an Informa Company. November 30, 1987. Retrieved 12 January 2016. 
  4. ^ Smith, JT; Pounder, RE (March 1990). "Sufotidine 600 mg bd Virtually Eliminates 24 hour Intragastric Acidity in Duodenal Ulcer Subjects". Gut. 31 (3): 291–3. doi:10.1136/gut.31.3.291. PMC 1378269Freely accessible. PMID 1969833. 
  5. ^ Fiorucci, S; Santucci, L; Farroni, F; Pelli, MA; Morelli, A (October 1989). "Effect of Omeprazole on Gastroesophageal Reflux in Barrett's Esophagus". The American Journal of Gastroenterology. 84 (10): 1263–7. PMID 2801676. 
  6. ^ Ganellin, C.R.; Triggle, D.J., eds. (1999). Dictionary of Pharmacological Agents (1st ed.). London: Chapman & Hall. ISBN 9780412466304. 
  7. ^ Lawton, G.; Witty, D.R., eds. (2011). Progress in Medicinal Chemistry. Vol. 50 (1st ed.). London: Academic. p. 36. ISBN 978-0-12-381290-2. 
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sufotidine&oldid=732353822"